Clin2
NCT07481357Possibly a fitRecruiting

DA 3501 for advanced stomach or pancreatic cancer

Gastric (Stomach) CancerGastroEsophageal CancerPancreatic Ductal Adenocarcinoma (mPDAC)

Part of Cancer, Digestive system clinical trials.

This trial tests a new drug, DA 3501, in people with advanced stomach or pancreatic cancer that has a specific protein called CLDN18.2. It aims to see if the drug is safe and effective.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
51 people
Ages
19 years and older
Study type
Interventional

Who can take part

  • You are 19 years old or older
  • You have advanced stomach, gastro-esophageal junction, or pancreatic cancer that has the CLDN18.2 protein
  • Your cancer can be measured on scans
  • You are expected to live at least 12 weeks

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07108504Not yet recruiting· Phase 2
LM-302 plus gemcitabine for advanced pancreatic cancer with CLDN18.2

This trial tests a new drug, LM-302, combined with gemcitabine for people with a specific type of advanced pancreatic cancer that has not responded to or stopped working on first-line treatment. The goal is to see if the combination is safe and effective.

NCT07235202Recruiting· Phase 1/Phase 2
MR001 plus chemo for advanced pancreatic cancer after first treatment

This trial tests a new drug, MR001, combined with chemotherapy for people whose pancreatic cancer has spread and no longer responds to their first treatment. It aims to see if this combination can help shrink tumors or slow the disease.

Beijing, Beijing Municipality
NCT06921837Recruiting· Phase 1/Phase 2
BDC-4182 for advanced gastric or gastroesophageal cancer

This trial tests a new drug called BDC-4182 for advanced gastric or gastroesophageal cancer. It is for people who have already tried standard treatments and may target a protein called Claudin 18 on some cancer cells.

Darlinghurst, New South Wales
NCT06005493Recruiting· Phase 1/Phase 2
Study of AZD5863 for advanced stomach, esophagus, or pancreatic cancer

This trial is testing an investigational drug called AZD5863 for people whose stomach, esophagus, or pancreatic cancer has spread and hasn't responded to at least one previous treatment. The study aims to see if targeting a protein called Claudin 18.2 on tumor cells can help shrink or slow the cancer.

Jacksonville, Florida
NCT06472037Recruiting· Phase 2
AG chemo plus immunotherapy and short radiation for locally advanced pancreatic cancer

This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.

Tianjin, Tianjin Municipality
NCT06219941Recruiting· Phase 2
Studying AZD0901 for Claudin18.2-positive advanced solid tumors

This trial tests a new drug called AZD0901 for people with advanced solid tumors that have a specific protein on their surface. It aims to see if the drug can shrink or slow the growth of these tumors.

Orange, California

Hear when a new Gastric (Stomach) Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.